Drugs / FTC/TDF
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01565889 | Mar 2012 → Aug 2013 | HIV infectious disease, hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-10-24 | Gilead Sciences | Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens gilead.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FTC/TDF | “FTC/TDF (200/300 mg) FDC tablet administered orally once daily” NCT01565889 ↗ |
| Route | Oral | “administered orally once daily” NCT01565889 ↗ |